Dan Skovronsky, Eli Lilly CSO (courtesy Purdue University)

Eli Lil­ly's IL-23 in­hibitor mirik­izum­ab shows late-stage promise in ul­cer­a­tive col­i­tis — but Ab­b­Vie's Skyrizi looms

As one of the key dri­vers in Eli Lil­ly’s mis­sion to re­vamp its pipeline, IL-23 in­hibitor mirik­izum­ab has come out swing­ing against po­ten­tial com­peti­tor Cosen­tyx and has looked to score a big win as the first ul­cer­a­tive col­i­tis ther­a­py in its class. Now, that big ap­proval is one step clos­er.

In a 12-week Phase III in­duc­tion study dubbed LU­CENT-1, Lil­ly’s mirik­izum­ab beat out place­bo at con­trol­ling or re­solv­ing ul­cer­a­tive col­i­tis pa­tients’ symp­toms, the drug­mak­er said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.